Sanofi: eosinophilic esophagitis meets both primary endpoint

(CercleFinance.com) - Sanofi and Regeneron announce positive results from Part A of the pivotal Phase III trial evaluating Dupixent (dupilumab) in the treatment of eosinophil esophagitis in patients 12 years of age and older, with the drug having met both co-primary endpoints.


Both health groups report that Dupixent has demonstrated significant clinical and anatomic improvements, including an improvement in dysphagia, with a 69% reduction in symptoms under Dupixent, compared to 32% for placebo.

"Dupixent is the first and only biologic to show positive and clinically-meaningful results in this population as part of a Phase 3 trial," the companies said, adding that Part B of the trial is underway.


Copyright (c) 2020 CercleFinance.com. All rights reserved.